

States with Comprehensive Medical Marijuana Laws

A-1. State/ Jurisdiction	B-1. Organization and Program Name*	C-1. Statutory Language (Year)	D-1. Registry or ID Card	E-1. Fee to Receive Card/ Register (for Patients)#	F-1. Cultivation**	G-1. Possession Limits***##	H-1. Dispensaries	I-1. Specifies Conditions	J-1. List of Conditions###	K-1. Recognizes Patients from Other States	L-1. Recreational Use (Adult Use)
Alabama	Alabama Medical Cannabis Commission	SB46 (2021)	Yes	\$65	Yes	60 daily doses at one time (1 dose=50mg)	Yes	Yes	Autism Sprectrum Disorder (ASD); Cancer-related cachexia, nausea or vomiting, weight loss or chronic pain; Crohn's Disease; depression; epilepsy or a condition causing seizures; HIV/AIDS-related nausea or weight loss; panic disorder; Parkinson's disease; persistent nausea that is not significantly responsive to traditional treatment, except for nausea related to pregnancy, cannabis-induced cyclical vomiting syndrome, or cannabinoid hyperemesis syndrome; Post Traumatic Stress Disorder (PTSD); Sickle Cell Anemia; spasticity associated with a motor neuron disease, including Amyotrophic Lateral Sclerosis; spasticity associated with multiple sclerosis or a spinal cord injury; a terminal illness; Tourette's Syndrome; a condition causing chronic or intractable pain in which conventional therapeutic intervention and opiate; and therapy is contraindicated or has proved ineffective.	No	No
Alaska	Department of Health & Social Services, Bureau of Vital Statistics; Marijuana Registry, Alcohol and Marijuana Control Office	Measure 8 (1998) SB 94 (1999) Statute Title 17, Chapter 37	Yes	\$25	Yes, 6 plants with maximum of 3 mature ones	1 oz. per day	No, but recreational retail stores	Yes, for AK approved conditions, but not for dispensary purchases	Cancer, glaucoma, HIV/AIDS, any chronic or debilitating disease or treatment for such diseases, which produces conditions that may be alleviated by the medical use of the marijuana: cachexia; severe pain; severe nausea; seizures, including those that are characteristic of epilepsy; or persistent muscle spasms, including those that are characteristic or multiple sclerosis. Other conditions are subject to approval by the Alaska Department of Health and Social Services.	No	Yes, Ballot Measure 2 (2014)
Arizona	Department of Health Services, Medical Marijuana Program	Proposition 203 (2010)	Yes	\$150; reduced \$75	Yes, 12 plants if more than 25 miles away from dispensary	2.5 oz.	Yes	Yes	Cancer, glaucoma, HIV/AIDS, Hepatitis C, ALS, Crohn's disease, Alzheimer's disease, cachexia or wasting syndrome, PTSD, severe and chronic pain, severe nausea, seizures (including epilepsy), severe or persistent muscle spasms (including multiple sclerosis).	Yes, for AZ-approved conditions, but not for dispensary purchases.	Yes, Proposition 207 (2020)
Arkansas	Department of Health	Issue 6 (2016)	Yes	\$50	No	2.5 oz. in 14-day period	Yes	Yes	Cancer, glaucoma, HIV/AIDS, hepatitis C, ALS, Tourette's syndrome, Crohn's disease, ulcerative colitis, PTSD, severe arthritis, fibromyalgia, Alzheimer's disease; A chronic or debilitating disease or medical condition or its treatment that produces one or more of the following: cachexia or wasting syndrome; peripheral neuropathy; intractable pain, which is pain that has not responded to ordinary medications, treatment, or surgical measures for more than six months; severe nausea; seizures, including without limitation those characteristic of epilepsy; or severe and persistent muscle spasms, including without limitation those characteristic of multiple sclerosis; Any other medical condition or its treatment approved by the Department of Health.	Yes	No
California	Department of Public Health, Medical Marijuana Program; Bureau of Medical Cannabis Regulation	Proposition 215 (1996) SB 420 (2003)	Yes	Between \$50 and \$100	Yes, 6 mature or 12 immature plants	8 oz. or amount recommended by a physician	Yes, licensed through local and county ordinances	Yes	AIDS, anorexia, arthritis, cachexia, cancer, chronic pain, glaucoma, migraine, persistent muscle spasms, including spasms associated with multiple sclerosis, seizures, including seizures associated with epilepsy, severe nausea; Other chronic or persistent medical symptoms.	No	Yes, Proposition 64 (2016)
Colorado	Department of Public Health & Environment, Med. Marijuana Registry	Amendment 20 (2000)	Yes	\$25; fee might be waived	Yes, 6 plants with a maximum of 3 mature ones	2 oz.	Yes	Yes	Cancer, glaucoma, HIV/AIDS positive, cachexia; severe pain; severe nausea; seizures, including those that are characteristic of epilepsy; persistent muscle spasms, including those that are characteristic of multiple sclerosis; PTSD; autism spectrum disorder; and all conditions for which opioids could be prescribed to treat. Other conditions are subject to approval by the Colorado Board of Health	No	Yes, Amendment 64 (2012)
Connecticut	Department of Consumer Protection, Medical Marijuana Program	HB 5389 (2012)	Yes	\$100	No	2.5 oz.	Yes	Yes	Cancer, glaucoma, HIV/AIDS, Parkinson's Disease, multiple sclerosis, damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity, epilepsy, cachexia, wasting syndrome, Crohn's Disease, Post-Traumatic Stress Disorder (PTSD), sickle cell disease, post laminectomy syndrome with chronic radiculopathy, severe psoriasis and psoriatic arthritis, ALS, ulcerative colitis, Complex Regional Pain Syndrome, cerebral palsy, cystic fibrosis, irreversible spinal cord injury with objective neurological indication of intractable spasticity, terminal illness requiring end-of-life care, uncontrolled intractable seizure disorder, spasticity or neuropathic pain associated with fibromyalgia, severe rheumatoid arthritis, post herpetic neuralgia, hydrocephalus with intractable headache, intractable headache syndromes, neuropathic facial pain, muscular dystrophy, osteogenesis imperfecta, and chronic neuropathic pain associated with degenerative spinal disorders.	No	No

A-1. State/Jurisdiction	B-1. Organization and Program Name*	C-1. Statutory Language (Year)	D-1. Registry or ID Card	E-1. Fee to Receive Card/ Register (for Patients)#	F-1. Cultivation**	G-1. Possession Limits***##	H-1. Dispensaries	I-1. Specifies Conditions	J-1. List of Conditions###	K-1. Recognizes Patients from Other States	L-1. Recreational Use (Adult Use)
Delaware	Department of Health & Social Services, Division of Public Health, Medical Marijuana Program	SB 17 (2011)	Yes	\$50	No	6 oz.	Yes	Yes	Terminal illness, cancer, HIV/AIDS, decompensated cirrhosis, ALS, agitation of Alzheimer's disease, Post-Traumatic Stress Disorder (PTSD), intractable epilepsy, autism with aggressive behavior, glaucoma, chronic debilitating migraine; A chronic or debilitating disease or medical condition or its treatment that produces cachexia or wasting syndrome, severe, debilitating pain that has not responded to previously prescribed medication or surgical measure for more than three months, or for which other treatment options produced serious side effects, intractable nausea, seizures, or severe and persistent muscle spasms, including but not limited to those characteristic of Multiple Sclerosis.	Yes, for DE-approved conditions.	No
District of Columbia	Department of Health, Med. Marijuana Program	Initiative 59 (1998) L18-0210 (2010)	Yes	100; reduced fee \$25	No	2 oz. dried per month (Through rulemaking, Mayor may increase the quantity of dried medical marijuana that may be possessed 4 oz.)	Yes	Yes	HIV, AIDS, cancer, glaucoma, conditions characterized by severe and persistent muscle spasms, such as multiple sclerosis; patients undergoing chemotherapy or radiotherapy, using azidothymidine or protease inhibitors, decompensated cirrhosis, Lou Gehrig's disease, Cachexia or wasting syndrome, Alzheimer's Disease, and seizure disorders.	No	Yes, Initiative 71 (2014)
Florida	Department of Health, Office of Medical Marijuana Use	Amendment 2 (2016)	Yes	\$75	No	Possess a 70-day supply or 4 oz.; purchase a 35-day, or no more than 2.5 oz.	Yes	Yes	Cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, multiple sclerosis, a terminal condition diagnosed by a physician other than the qualified physician issuing the physician certification, and chronic nonmalignant pain caused by a qualifying medical condition or that originates from a qualifying medical condition and persists beyond the usual course of that qualifying medical condition.	No	No
Hawaii	Department of Health, Medical Marijuana Program	SB 862 (2000)	Yes	\$38.50 (\$35 application fee + \$3.50 portal administration fee); 2 year renewal (\$77)	Yes, 7 plants	4 oz.	Yes	Yes	Amyotrophic Lateral Sclerosis (ALS), cancer, glaucoma, lupus, epilepsy, multiple sclerosis, rheumatoid arthritis, HIV/AIDS, PTSD; a chronic or debilitating disease or medical condition or its treatment that produces one or more of the following: Cachexia or wasting syndrome, severe pain, severe nausea, seizures, severe and persistent muscle spasms including those characteristic of multiple sclerosis or Crohn's disease.	No	No
Illinois	Department of Public Health, Division of Medical Cannabis	HB 1 (2013) Eff. 1/1/2014 Rules Adult use legalization SB 0007 bill passed legislature May, 2019, signed by governor June 25, 2019, Effective Jan. 1, 2020.	Yes	\$100 fee; reduced application fee \$50	No	2.5 oz. in 14-day period	Yes	Yes	Alzheimer's disease, HIV/AIDS, Amyotrophic lateral sclerosis (ALS), Arnold-Chiari malformation, cancer, causalgia, chronic inflammatory demyelinating polyneuropathy, Crohn's disease, CRPS (complex regional pain syndrome Type II), dystonia, fibrous dysplasia, glaucoma, hepatitis C, hydrocephalus, hydromyelia, interstitial cystitis, lupus, multiple sclerosis, muscular dystrophy, myasthenia gravis, myoclonus, nail-patella syndrome, neurofibromatosis, Parkinson's disease, post-concussion syndrome, reflex sympathetic dystrophy, residual limb pain, rheumatoid arthritis, seizures (including those characteristic of epilepsy), severe fibromyalgia, Sjogren's syndrome, spinal cord disease (including but not limited to arachnoiditis), spinal cord injury, spinocerebellar ataxia, syringomyelia, Tarlov cysts, tourette syndrome, traumatic brain injury, and cachexia/wasting syndrome, alternative to opioid treatment, autism, chronic pain, irritable bowel syndrome, migraines, osteoarthritis, anorexia nervosa, Ehler-Danlos Syndrome, Neuro-Behcet's Autoimmune Disease, neuropathy, polycystic kidney disease, PTSD, superior canal dehiscence syndrome, and terminal illness with a life expectancy of fewer than six months.	No	Yes, Measure approved by legislature in May, 2019, signed by governor June 25, 2019. Effective Jan. 1, 2020
Louisiana	Department of Agriculture and Forestry (LDAF)	SB 271 (2017)	Pending	Unclear	No	30-day supply	Yes	Yes	Cancer, HIV/AIDS, cachexia or wasting syndrome, seizure disorders, epilepsy, spasticity, Crohn's disease, muscular dystrophy, multiple sclerosis, glaucoma, Parkinson's disease, severe muscle spasms, intractable pain, and post traumatic disorder (PTSD), and four conditions associated with autism spectrum disorder.	No	No
Maine	Department of Health & Human Services, Division of Licensing & Regulatory Services, Maine Medical Use of Marijuana Program (MMMP)	Question 2 (1999) LD 611 (2002) Question 5 (2009) LD 1811 (2010) LD 1296 (2011)	Yes	No fee	Yes, 6 mature plants/12 immature in enclosed, locked location	2.5 oz.	Yes	Yes	Cancer, glaucoma, HIV, acquired immune deficiency syndrome, hepatitis C, amyotrophic lateral sclerosis, Crohn's disease, Alzheimer's, nail-patella syndrome, chronic intractable pain, cachexia or wasting syndrome, severe nausea, seizures (epilepsy), severe and persistent muscle spasms, and multiple sclerosis.	Yes, but not for dispensary purchases	Yes, Question 1 (2016) page 4 Chapter 409 (2018)

A-1. State/Jurisdiction	B-1. Organization and Program Name*	C-1. Statutory Language (Year)	D-1. Registry or ID Card	E-1. Fee to Receive Card/ Register (for Patients)#	F-1. Cultivation**	G-1. Possession Limits***##	H-1. Dispensaries	I-1. Specifies Conditions	J-1. List of Conditions###	K-1. Recognizes Patients from Other States	L-1. Recreational Use (Adult Use)
Maryland	Department of Health & Mental Hygiene, Maryland Medical Cannabis Commission	HB 702 (2003) SB 308 (2011) HB 180/ SB 580 (2013) HB 1101- Chapter 403 (2013) SB 923 (signed 4/14/14); HB 881- similar to SB 923	Yes	\$50	No	30-day supply, 120g usable product/36g of THC if infused	Yes	Yes	A chronic or debilitating disease or medical condition that causes: cachexia, anorexia, wasting syndrome, severe or chronic pain, severe nausea, seizures, severe or persistent muscle spasms, glaucoma, post-traumatic stress disorder (PTSD), "or another chronic medical condition which is severe and for which other treatments have been ineffective.	No	No
Massachusetts	Cannabis Control Commission	Question 3 (2012) Regulations (2013)	Yes	No fee	Yes, only if patient has a verified hardship in accessing a treatment center	10 oz., 60-day supply	Yes	Yes	Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune deficiency syndrome (AIDS), hepatitis C, amyotrophic lateral sclerosis (ALS), Crohn's disease, Parkinson's disease, multiple sclerosis and other conditions as determined in writing by a qualifying patient's physician.	No	Yes, Question 4 (2016)
Michigan	Department of Licensing & Regulatory Affairs, Michigan Medical Marijuana Program	Proposal 1 (2008)	Yes	\$40	Yes, 12 plants kept in enclosed locked facility	2.5 oz.	Not in state law, but localities may create ordinances to allow them and regulate them.	Yes	Approved for treatment of debilitating medical conditions, defined as cancer, glaucoma, HIV, AIDS, hepatitis C, amyotrophic lateral sclerosis, Crohn's disease, agitation of Alzheimer's disease, nail patella, cachexia or wasting syndrome, severe and chronic pain, severe nausea, seizures, epilepsy, muscle spasms, multiple sclerosis, PTSD, arthritis, autism, chronic pain, colitis, inflammatory bowel disease, obsessive compulsive disorder, Parkinson's, Rheumatoid arthritis, spinal cord injury, Tourette's syndrome, and ulcerative colitis.	Yes, for legal protection of possession, but not for dispensary purchases.	Yes, Proposal 18-1 (2018)
Minnesota	Department of Health, Medical Cannabis	SF 2471, Chapter 311 (2014)	Yes	\$200; reduced fee \$50	No	90-day supply	Yes, limited, liquid extract products only	Yes	Cancer associated with severe/chronic pain, nausea or severe vomiting, or cachexia or severe wasting, glaucoma, HIV/AIDS, Tourette Syndrome, Amyotrophic lateral sclerosis (ALS), seizures, including those characteristic of epilepsy, severe and persistent muscle spasms, including those characteristic of multiple sclerosis. inflammatory bowel disease, including Crohn's disease, terminal illness, with a probable life expectancy of less than one year, intractable pain, post-traumatic stress disorder, autism, obstructive sleep apnea, Alzheimer's disease, chronic pain, sickle cell disease, chronic motor or vocal tic disorder	No	No
Missouri	Department of Health and Senior Services	Amendment 2 (2018)	Yes	\$25.58 (submitted before 06/30/2021); \$25.94 (submitted after 07/01/2021)	Yes, 6 plants w/cultivation registration	4 oz. in 30 days	Yes, details pending	Yes	Cancer, epilepsy, glaucoma, intractable migraines unresponsive to other treatment, chronic medical condition that causes severe, persistent pain or persistent muscle spasms, including multiple sclerosis, seizures, Parkinson's disease, and Tourette's syndrome, debilitating psychiatric disorders, including PTSD, HIV/AIDS, chronic medical condition normally treated with a prescription medication that could lead to physical or psychological dependence, terminal illness, or any other condition in the professional judgment of a physician, such as hepatitis C, ALS, IBD, Crohn's disease, Huntington's disease, autism, neuropathies, sickle cell anemia, Alzheimer's, cachexia, and wasting syndrome.	To be determined	No
Montana	Montana Department of Revenue	Initiative 148 (2004) SB 423 (2011) Initiative 182 (2016)	Yes	\$30	Yes, 4 mature plants	1 oz. per day; 5 oz. per month	Yes	Yes	Cancer, glaucoma, or positive status for HIV/AIDS, or the treatment of these conditions; a chronic or debilitating disease or medical condition or its treatment that produces cachexia or wasting syndrome, severe or chronic pain, severe nausea, seizures, including seizures caused by epilepsy, or severe or persistent muscle spasms, including spasms caused by multiple sclerosis or Crohn's disease; admittance to hospice care; painful peripheral neuropathy, a central nervous system disorder resulting in chronic, painful spasticity or muscle spasms, or PTSD.	No	Yes, Initiative 190 (2020)
Nevada	Department of Health and Human Services, Division of Public and Behavioral Health, Medical Marijuana Program	Question 9 (2000) NRS 453A NAC 453A	Yes	\$50 for 1 year and \$100 for 2 years	Yes, 12 plants if more than 25 miles away from dispensary	2.5 oz.	Yes	Yes	AIDS; cancer; glaucoma; and any medical condition or treatment to a medical condition that produces cachexia, persistent muscle spasms (including multiple sclerosis) or seizures (including epilepsy), severe nausea or pain, and PTSD. Other conditions are subject to approval by the health division of the state Department of Human Resources.	Yes, if the other state's program are "substantially similar." Patients must fill out Nevada paperwork. Adults over 21 may also purchase at adult retail dispensaries	Yes, Question 2 (2016)

A-1. State/Jurisdiction	B-1. Organization and Program Name*	C-1. Statutory Language (Year)	D-1. Registry or ID Card	E-1. Fee to Receive Card/ Register (for Patients)#	F-1. Cultivation**	G-1. Possession Limits***##	H-1. Dispensaries	I-1. Specifies Conditions	J-1. List of Conditions###	K-1. Recognizes Patients from Other States	L-1. Recreational Use (Adult Use)
New Hampshire	New Hampshire Health and Human Services, Therapeutic Use of Cannabis Program	HB 573 (2013)	Yes	\$50	No	2 oz. in 10-day period	Yes	Yes	Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, hepatitis C currently receiving antiviral treatment, amyotrophic lateral sclerosis, muscular dystrophy, Crohn's disease, multiple sclerosis, chronic pancreatitis, spinal cord injury or disease, traumatic brain injury, epilepsy, lupus, Parkinson's disease, Alzheimer's disease, or one or more injuries that significantly interferes with daily activities as documented by the patient's provider; a severely debilitating or terminal medical condition or its treatment that has produced at least one of the following: elevated intraocular pressure, cachexia, chemotherapy-induced anorexia, wasting syndrome, agitation of Alzheimer's disease, severe pain that has not responded to previously prescribed medication or surgical measures or for which other treatment options produced serious side effects, constant or severe nausea, moderate to severe vomiting, seizures, or severe, persistent muscle spasms." Also: Hepatitis C, moderate to severe chronic pain, and moderate or severe post-traumatic stress disorder (PTSD), Ehlers-Danlos syndrome, and severe pain that has not responded to previously prescribed medication or surgical measures or for which other treatment options produced serious side effect.	Yes, with a note from their home state, but they cannot purchase through dispensaries.	No
New Jersey	Department of Health, Medical Marijuana Program	SB 119 (2009)	Yes	\$100; reduced \$20	No	3 oz. in 30-day period	Yes	Yes	Amyotrophic lateral sclerosis (ALS), anxiety, cancer, chronic pain, dysmenorrhea, glaucoma, inflammatory bowel disease including Crohn's disease, intractable skeletal , spasticity, migraine, multiple sclerosis, muscular dystrophy, Opioid Use Disorder, positive status for Human Immunodeficiency Virus (HIV) and Acquired Deficiency Syndrome (AIDS), Post-Traumatic Stress Disorder (PTSD), seizure disorder including epilepsy, terminal illness with prognosis of less than 12 months to live, Tourette Syndrome.	No	Yes, Public Question 1 passed by voters in 2020 to allow legislature to enact legislation NJ AB 21 passed legislature, signed by governor March 1, 2021
New Mexico	Department of Health, Medical Cannabis Program	SB 523 (2007)	Yes	No fee	Yes, 16 plants 4 mature plants and 12 immature w/ permit	8 oz. in 90-day period	Yes	Yes	Amyotrophic Lateral Sclerosis (Lou Gehrig's disease); cancer; Crohn's disease; epilepsy; glaucoma; hepatitis C infection currently receiving antiviral treatment; HIV/AIDS; Huntington's Disease; hospice care; inclusion body myositis; inflammatory autoimmune-mediated arthritis; intractable nausea/vomiting; multiple sclerosis; damage to the nervous tissue of the spinal cord; painful peripheral neuropathy; Parkinson's disease; PTSD; severe chronic pain; severe anorexia/cachexia; spasmodic torticollis; ulcerative colitis.	No	Yes, HB 2 Cannabis regulation act passed legislature March 31, 2021 and signed by governor on 4/12/21.
New York	Department of Health, N.Y. State Medical Marijuana Program	A6357 (2014) Signed by governor 7/5/14	Yes	\$50	No	30-day supply	Yes	Yes	Cancer, positive status for human immunodeficiency virus or acquired immune deficiency syndrome, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity, epilepsy, inflammatory bowel disease, neuropathies, Huntington's disease, post-traumatic stress disorder, pain that degrades health and functional capability where the use of medical cannabis is an alternative to opioid use, substance use disorder, Alzheimer's, muscular dystrophy, dystonia, rheumatoid arthritis, autism or any other condition certified by the practitioner.	No	Yes, AB 1248A/SB 854 passed legislature, signed by governor on March 31, 2021.
North Dakota	Department of Health	Measure 5 (2016) NDCC 19-24.1 NDAC 33-44	Yes	\$50	No	3 oz. in 14-day period	Yes	Yes	Cancer, HIV/AIDS, hepatitis C, ALS, PTSD, Alzheimer's disease, dementia, Crohn's disease, fibromyalgia, spinal stenosis or chronic back pain including neuropathy or damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity, glaucoma, epilepsy; A chronic or debilitating disease medical condition or its treatment that produces one or more of the following: cachexia or wasting syndrome, severe debilitating pain that has not responded to previously prescribed medication or surgical measures for more than three months or for which other treatment options produced serious side effects, intractable nausea, seizures, or severe and persistent muscle spasms, including but not limited to those characteristic of multiple sclerosis; Any other medical condition or its treatment added by the North Dakota Department of Health.	No	No
Ohio	Board of Pharmacy, Medical Marijuana Control Program	HB 523 (2016) Approved by legislature, signed by governor 6/8/16	Yes	\$50	No	90-day supply	Yes	Yes	AIDS/HIV, Alzheimer's disease, ALS, cancer, chronic traumatic encephalopathy, Crohn's disease, epilepsy, fibromyalgia, glaucoma, hepatitis C, inflammatory bowel disease, multiple sclerosis, chronic, severe, or intractable pain, Parkinson's disease, PTSD, sickle cell anemia, spinal cord disease or injury, Tourette's syndrome, traumatic brain injury, and ulcerative colitis.	Details pending, but will require reciprocity.	No

A-1. State/Jurisdiction	B-1. Organization and Program Name*	C-1. Statutory Language (Year)	D-1. Registry or ID Card	E-1. Fee to Receive Card/ Register (for Patients)#	F-1. Cultivation**	G-1. Possession Limits***##	H-1. Dispensaries	I-1. Specifies Conditions	J-1. List of Conditions###	K-1. Recognizes Patients from Other States	L-1. Recreational Use (Adult Use)
Oklahoma	Department of Health, Medical Marijuana Authority	SQ 788 Approved by voters on 6/26/18	Yes	\$100; reduced \$20	Yes, 12 plants (6 mature, 6 immature)	3 oz.	Yes	Not as voted on	There is no list of approved conditions. According to the law, "A medical marijuana license must be recommended according to the accepted standards a reasonable and prudent physician would follow when recommending or approving any medication"	Yes, a temporary license may be issued if the patient proves they are a member of another state's regulated medical marijuana program.	No
Oregon	Department of Human Services, Medical Marijuana Dispensary Program	Oregon Medical Marijuana Act (1998) SB 161 (2007)	Yes	\$200; reduced \$60	Yes, 6 mature/18 immature at registered grow sites for no more than 4 people	24 oz. flower, 16 oz. solid form	Yes	Yes	Cancer, glaucoma, degenerative or pervasive neurological condition; positive status for HIV/AIDS, or treatment for these conditions; A medical condition or treatment for a medical condition that produces cachexia, severe pain, severe nausea, seizures, including seizures caused by epilepsy, or persistent muscle spasms, including spasms caused by multiple sclerosis. Other conditions are subject to approval by the Health Division of the Oregon Department of Human Resources.	No	Yes, Measure 91 (2014)
Pennsylvania	Department of Health, Medical Marijuana Program	SB 3 (2016) Signed by governor 4/17/16	Yes	\$50	No	30-day supply	Yes	Yes	Amyotrophic lateral sclerosis (ALS), anxiety disorders, autism, cancer, Crohn's disease, damage to the nervous tissue of the central nervous system (brain-spinal cord) with objective neurological indication of intractable spasticity and other associated neuropathies, dyskinetic and spastic movement disorders, epilepsy, glaucoma, HIV/AIDS, Huntington's disease, inflammatory bowel disease, intractable seizures, multiple sclerosis, neurodegenerative diseases, neuropathies, opioid use disorder for which conventional therapeutic interventions are contraindicated or ineffective, Parkinson's disease, PTSD, severe chronic or intractable pain of neuropathic origin or severe chronic or intractable pain, sickle cell anemia, terminal illness, Tourette syndrome.	No	No
Rhode Island	Department of Health, Medical Marijuana Program	S 710 B (2006)- Legislature overturned governor's veto. SB 791 (2007) SB 185 (2009)	Yes	\$50; reduced \$25	Yes, 24 plants (12 mature plants and 12 immature plants)	2.5 oz. in 30 days	Yes	Yes	Cancer, glaucoma, positive status for HIV/AIDS, Hepatitis C, or the treatment of these conditions; A chronic or debilitating disease or medical condition or its treatment that produces cachexia or wasting syndrome; severe, debilitating, chronic pain; severe nausea; seizures, including but not limited to, those characteristic of epilepsy; or severe and persistent muscle spasms, including but not limited to, those characteristic of multiple sclerosis or Crohn's disease; or agitation of Alzheimer's Disease; or any other medical condition or its treatment approved by the state Department of Health.	Yes, but only for conditions approved in RI	No
South Dakota Adult-use measure ruled unconstitutional as of Feb. 9, 2021.	Department of Health	Initiated Measure 26 (2020) News: Court rules measure unconstitutional Feb. 8, 2021 News: AG will not appeal court decision Feb. 12, 2021 News: Legislature considering legislation Feb. 9, 2021	Yes	Unclear	Yes, 3 plants or more by Department of Health	3 oz.	Yes	Yes	A chronic or debilitating disease or medical condition or its treatment that produces one or more of the following: cachexia or wasting syndrome; severe, debilitating pain; severe nausea; seizures; or severe and persistent muscle spasms, including, those characteristic of multiple sclerosis; or... Any other medical condition or its treatment added by the department, as provided for in section 26 of this act.	Yet to be determined	Amendment A (2020) Overturned by Courts Feb. 8, 2021 Not counted in the sates tally
Utah	Utah Department of Health, Utah Medical Cannabis Program	Prop 2 (2018) replaced by HB 3001 HB 3001 2018- Third Special Session	Yes	\$15	No	113g flower or 20g THC	Yes	Yes	HIV/AIDS; Alzheimer's disease; ALS; cancer; cachexia; persistent nausea that is not significantly responsive to traditional treatment, except for nausea related to pregnancy, cannabis-induced cyclical vomiting syndrome, or cannabinoid hyperemesis syndrome; Crohn's disease or ulcerative colitis; epilepsy; multiple sclerosis or persistent and debilitating muscle spasms; PTSD (under specific conditions); autism; a terminal illness when the patient's remaining life expectancy is less than six months; a condition resulting in the individual receiving hospice care; a rare condition or disease that affects fewer than 200,000 individuals in the United States; and pain (under specific conditions).	Yet to be determined	No

A-1. State/Jurisdiction	B-1. Organization and Program Name*	C-1. Statutory Language (Year)	D-1. Registry or ID Card	E-1. Fee to Receive Card/Register (for Patients)#	F-1. Cultivation**	G-1. Possession Limits***##	H-1. Dispensaries	I-1. Specifies Conditions	J-1. List of Conditions###	K-1. Recognizes Patients from Other States	L-1. Recreational Use (Adult Use)
Vermont	Department of Public Safety, Division of Criminal Justice Services, Marijuana Registry	SB 76 (2004) SB 7 (2007) SB 17 (2011) H.511 (2018)	Yes	\$50	Yes, 2 mature plants in enclosed, locked facility	2 oz. in 30 days	Yes	Yes	Cancer, AIDS, positive status for HIV, multiple sclerosis, glaucoma, or the treatment of these conditions if the disease or the treatment results in severe, persistent, and intractable symptoms; or a disease, medical condition, or its treatment that is chronic, debilitating and produces severe, persistent, and one or more of the following intractable symptoms: cachexia or wasting syndrome, chronic pain or nausea or seizures. On June 11, 2017, Gov. Phil Scott (R) signed S.16 into law, adding Parkinson's disease, Crohn's disease, and PTSD.	No	Yes, H.511 approved by legislature, signed by governor 1/22/18. Effective July 1, 2018. S.54 (2020) establishes sales regulations. Effective Oct. 7, 2020.
Virginia	Virginia Department of Health Professions and the Pharmacy Board	H 1460 (2020) S 646 (2020) H 1617 (2020) S 976 (2020)	Yes	\$50	No	90-day supply	Yes	No	All medical conditions may qualify.	No, but allows for temporary residents to apply with approval from the Board of Pharmacy.	Yes, legislature approved HB2312 and SB1406. Signed by governor 4/7/21.
Washington	Department of Health, Medical Marijuana	Initiative 692 (1998) SB 5798 (2010) SB 5073 (2011)	No	\$1	Yes, 6 plants	3 oz.	Yes, approved as of Nov. 2012, stores opened in July 2014.	Yes	Cancer, HIV, multiple sclerosis, epilepsy or other seizure disorder, or spasticity disorders; Intractable pain, limited to pain unrelieved by standard medical treatments and medications; Glaucoma, either acute or chronic, limited to mean increased intraocular pressure unrelieved by standard treatments and medications; Crohn's disease with debilitating symptoms unrelieved by standard treatments or medications; Hepatitis C with debilitating nausea or intractable pain unrelieved by standard treatments or medications; Diseases, including anorexia, which result in nausea, vomiting, wasting, appetite loss, cramping, seizures, muscle spasms, or spasticity, when these symptoms are unrelieved by standard treatments or medications; Chronic renal failure requiring hemodialysis; PTSD; Traumatic brain injury.	No	Yes, Initiative 502 (2012); WAC Marijuana rules: Chapter 314-55 WAC
West Virginia	Department of Health and Human Resources, Bureau of Public Health	SB 386 (2017)	Yes	\$50	No	30-day supply	Yes	Yes	Chronic or debilitating diseases or medical conditions that result in a patient being admitted into Hospice or receiving palliative care; chronic or debilitating diseases or medical conditions or the treatment of chronic or debilitating diseases or medical conditions that produce: Cachexia, anorexia, or wasting syndrome; severe or chronic pain that does not find effective relief through standard pain medication; severe nausea; seizures; severe or persistent muscle spasms; refractory generalized anxiety disorder; Post-traumatic stress disorder (PTSD).	No, but may allow terminally ill to buy in other states.	No

Source: National Conference of State Legislatures (NCSL) (as of May 18, 2021), Available at <https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx> (columns not indicated by an asterisk (*) or (#));

#, ##, ### KHI review of laws from included states (as of June 10, 2021);

*, **, *** Public Health Law Center (as of February 14, 2019). <https://www.networkforphl.org/wp-content/uploads/2020/01/Medical-Marijuana-Programs.pdf>

Note: The information provided in this table was identified through several sources of information. Jurisdictions may have adopted new or updated policies that were not identified by this approach and therefore are not identified properly in the table.

NCSL uses criteria similar to other organizations tracking this issue to determine if a program is "comprehensive":

- Protection from criminal penalties for using marijuana for a medical purpose;
- Access to marijuana through home cultivation, dispensaries or some other system that is likely to be implemented;
- It allows a variety of strains or products, including those with more than "low THC";
- It allows either smoking or vaporization of some kind of marijuana products, plant material or extract; and
- Is not a limited trial program. (South Dakota and Nebraska have limited, trial programs that are not open to the public.

Unclear = unable to locate information.

This table is accompanied by a related table that shows States with Limited Access Medical Marijuana Laws (Low THC/High CBD-Cannabidiol) (July 2021). Both tables and a blog post summarizing the information are accessible online at <https://www.khi.org/policy/article/21-45>.

A-1. State/Jurisdiction: indicates a state that has an approved medical marijuana program.

B-1. Organization and Program Name: specifies the entity responsible for administration of the specific state's medical marijuana program and provides links to relevant programs where available

C-1. Statutory Language (Year): notes legal provisions authorizing the use of marijuana for medical purposes in the jurisdiction and the year the program was first enacted.

D-1. Registry or ID Card: indicates if a jurisdiction established ID cards or a registry. An ID card is a document issued by a jurisdiction that identifies a person as a registered qualifying patient, a registered designated caregiver, a registered nonprofit medical marijuana dispensary agent or a registered independent third-party laboratory agent. A registry is a secure, electronic and online database for the registration of individuals, including qualified patients, caregivers and physicians.

E-1. Fee to Receive Card/Register (for Patients): indicates where patients and/or caregivers are required to pay a fee to obtain a card and specifies the fee amount.

F-1. Cultivation: indicates whether a jurisdiction allows qualified patients or designated caregivers to plant, grow, harvest marijuana for medical use.

G-1. Possession Limits: specifies the amount of marijuana a patient can possess with protection from criminal penalties.

H-1. Dispensaries: indicates whether the legal authority provides for the operation of dispensaries to distribute medical marijuana.

I-1. Specifies Conditions: indicates if a jurisdiction specified conditions that would allow an individual to receive access to medical marijuana.

J-1. List of Conditions: indicates conditions that would make an individual eligible to access marijuana.

K-1. Recognizes Patients from Other States: indicates if a jurisdiction recognizes patient medical marijuana privileges (ID cards) issued by another state.

L-1. Recreational Use (Adult Use): indicates whether the state allows for marijuana use for reasons other than medical necessity and provides links to the relevant legal authority.